Healthcare provider profile · identity verified

Amy Stark

Nurse Practitioner · OKLAHOMA CITY, OK · NPI 1477098754

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	134	44
Omeprazole	Omeprazole	122	34
Levothyroxine Sodium	Levothyroxine Sodium	109	37
Potassium Chloride	Potassium Chloride	102	34
Gabapentin	Gabapentin	99	35
Furosemide	Furosemide	98	38
Lisinopril	Lisinopril	90	29
Mirtazapine	Mirtazapine	73	22
Trazodone Hcl	Trazodone Hcl	71	26
Amlodipine Besylate	Amlodipine Besylate	68	27
Eliquis	Apixaban	66	19
Pantoprazole Sodium	Pantoprazole Sodium	59	23
Metoprolol Succinate	Metoprolol Succinate	57	17
Montelukast Sodium	Montelukast Sodium	52	15
Donepezil Hcl	Donepezil Hcl	45	13
Fluoxetine Hcl	Fluoxetine Hcl	42	suppressed
Sertraline Hcl	Sertraline Hcl	42	15
Famotidine	Famotidine	41	14
Carvedilol	Carvedilol	40	14
Rosuvastatin Calcium	Rosuvastatin Calcium	40	12
Albuterol Sulfate Hfa	Albuterol Sulfate	39	19
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	39	suppressed
Trulicity	Dulaglutide	39	suppressed
Memantine Hcl	Memantine Hcl	38	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	37	11
Clopidogrel	Clopidogrel Bisulfate	36	13
Nystatin	Nystatin	36	16
Fluticasone Propionate	Fluticasone Propionate	35	19
Losartan Potassium	Losartan Potassium	34	12
Tamsulosin Hcl	Tamsulosin Hcl	33	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Ezetimibe	Ezetimibe	32	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	32	14
Tramadol Hcl	Tramadol Hcl	31	15
Metformin Hcl	Metformin Hcl	29	11
Buspirone Hcl	Buspirone Hcl	28	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	26	suppressed
Torsemide	Torsemide	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Celecoxib	Celecoxib	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	23	21
Hydrochlorothiazide	Hydrochlorothiazide	22	suppressed
Meloxicam	Meloxicam	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Amiodarone Hcl	Amiodarone Hcl	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Olanzapine	Olanzapine	17	suppressed
Ondansetron Odt	Ondansetron	17	12
Sucralfate	Sucralfate	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Nystop	Nystatin	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Allopurinol	Allopurinol	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Colestipol Hcl	Colestipol Hcl	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Bumetanide	Bumetanide	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Glipizide	Glipizide	12	suppressed
Simvastatin	Simvastatin	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Baclofen	Baclofen	11	suppressed
Finasteride	Finasteride	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Zemaira	Alpha-1-Proteinase Inhibitor	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error